Microarray analysis of bladder smooth muscle from patients with myelomeningocele

Jennifer A. Hipp, Jason D. Hipp, James J. Yoo, Anthony Atala, Karl Erik Andersson

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

OBJECTIVE: To examine whether gene profiles can provide a molecular evaluation of the quality and therapeutic potential in patients with myelomeningocele (MM), by comparing genetic profiles of smooth muscle cells (SMCs) from healthy bladders and bladders from patients, to identify genes that are over- and under-expressed in MM bladder SMCs. MATERIAL AND METHODS: Bladder SM biopsies were obtained from 'healthy' subjects undergoing bladder surgery for vesico-ureteric reflux and from patients with a neurogenic bladder secondary to MM. Bladder SMCs were expanded in vitro and total RNA was isolated and hybridized to gene chips to evaluate the differential expression levels of 22 283 genes. Differentially expressed genes were identified by two methods. In the first analysis, we directly compared raw data sets of healthy SMCs to those derived from patients with MM. In the second analysis, we indirectly compared healthy SMCs and MM SMCs to a reference file, to create a genetic signature of genes that are over- and under-expressed in MM SMCs. RESULTS: The direct analysis identified 240 genes that were over-expressed and 104 that were under-expressed in MM SMCs. Gene ontology classifications were used to identify biological themes and pathways. Genes that were over-expressed in MM SMCs were involved in development: mesenchyme homeobox 2 (-fold change, 9.3); bone morphogenic protein 6 (4.0); fibroblast growth factor 2 (4.8); inhibin A (4.2), cartilage oliogomeric matrix protein (9.97); collagen 11A (6); collagen 5A2 (3) and collagen 1A1 (2.18). The indirect analysis identified 665 genes that were over-expressed and 1343 that were under-expressed in MM SMCs. Pathway-based analysis of these genetic signatures showed an over-expression of genes involved in muscle development and focal adhesion/extracellular matrix interactions. Genes that were under-expressed in MM SMCs were mapped to muscle contraction, transmission of nerve impulses, and cell-cell adhesion pathways. CONCLUSION: Our results are consistent with previous studies showing that MM bladders have an excess of extracellular matrix deposition, improper contraction, and are developmentally immature relatively to healthy SMCs. The clinical implication of microarray analysis of MM SMCs is that it provides potential targets that could induce muscle differentiation and inhibit extracellular matrix production.

Original languageEnglish
Pages (from-to)741-746
Number of pages6
JournalBJU International
Volume102
Issue number6
DOIs
StatePublished - Sep 1 2008
Externally publishedYes

Fingerprint

Meningomyelocele
Microarray Analysis
Smooth Muscle Myocytes
Smooth Muscle
Urinary Bladder
Genes
Extracellular Matrix
Collagen
Matrilin Proteins
Neurogenic Urinary Bladder
Gene Ontology
Focal Adhesions
Muscle Development
Homeobox Genes
Fibroblast Growth Factor 2
Mesoderm
Muscle Contraction
Oligonucleotide Array Sequence Analysis
Cell Adhesion
Action Potentials

Keywords

  • Bladder smooth muscle
  • Microarray
  • Myelomeningocele

ASJC Scopus subject areas

  • Urology

Cite this

Hipp, J. A., Hipp, J. D., Yoo, J. J., Atala, A., & Andersson, K. E. (2008). Microarray analysis of bladder smooth muscle from patients with myelomeningocele. BJU International, 102(6), 741-746. https://doi.org/10.1111/j.1464-410X.2008.07606.x

Microarray analysis of bladder smooth muscle from patients with myelomeningocele. / Hipp, Jennifer A.; Hipp, Jason D.; Yoo, James J.; Atala, Anthony; Andersson, Karl Erik.

In: BJU International, Vol. 102, No. 6, 01.09.2008, p. 741-746.

Research output: Contribution to journalArticle

Hipp, Jennifer A. ; Hipp, Jason D. ; Yoo, James J. ; Atala, Anthony ; Andersson, Karl Erik. / Microarray analysis of bladder smooth muscle from patients with myelomeningocele. In: BJU International. 2008 ; Vol. 102, No. 6. pp. 741-746.
@article{5cbf7bf8617e4aad85cef6fd328a1560,
title = "Microarray analysis of bladder smooth muscle from patients with myelomeningocele",
abstract = "OBJECTIVE: To examine whether gene profiles can provide a molecular evaluation of the quality and therapeutic potential in patients with myelomeningocele (MM), by comparing genetic profiles of smooth muscle cells (SMCs) from healthy bladders and bladders from patients, to identify genes that are over- and under-expressed in MM bladder SMCs. MATERIAL AND METHODS: Bladder SM biopsies were obtained from 'healthy' subjects undergoing bladder surgery for vesico-ureteric reflux and from patients with a neurogenic bladder secondary to MM. Bladder SMCs were expanded in vitro and total RNA was isolated and hybridized to gene chips to evaluate the differential expression levels of 22 283 genes. Differentially expressed genes were identified by two methods. In the first analysis, we directly compared raw data sets of healthy SMCs to those derived from patients with MM. In the second analysis, we indirectly compared healthy SMCs and MM SMCs to a reference file, to create a genetic signature of genes that are over- and under-expressed in MM SMCs. RESULTS: The direct analysis identified 240 genes that were over-expressed and 104 that were under-expressed in MM SMCs. Gene ontology classifications were used to identify biological themes and pathways. Genes that were over-expressed in MM SMCs were involved in development: mesenchyme homeobox 2 (-fold change, 9.3); bone morphogenic protein 6 (4.0); fibroblast growth factor 2 (4.8); inhibin A (4.2), cartilage oliogomeric matrix protein (9.97); collagen 11A (6); collagen 5A2 (3) and collagen 1A1 (2.18). The indirect analysis identified 665 genes that were over-expressed and 1343 that were under-expressed in MM SMCs. Pathway-based analysis of these genetic signatures showed an over-expression of genes involved in muscle development and focal adhesion/extracellular matrix interactions. Genes that were under-expressed in MM SMCs were mapped to muscle contraction, transmission of nerve impulses, and cell-cell adhesion pathways. CONCLUSION: Our results are consistent with previous studies showing that MM bladders have an excess of extracellular matrix deposition, improper contraction, and are developmentally immature relatively to healthy SMCs. The clinical implication of microarray analysis of MM SMCs is that it provides potential targets that could induce muscle differentiation and inhibit extracellular matrix production.",
keywords = "Bladder smooth muscle, Microarray, Myelomeningocele",
author = "Hipp, {Jennifer A.} and Hipp, {Jason D.} and Yoo, {James J.} and Anthony Atala and Andersson, {Karl Erik}",
year = "2008",
month = "9",
day = "1",
doi = "10.1111/j.1464-410X.2008.07606.x",
language = "English",
volume = "102",
pages = "741--746",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Microarray analysis of bladder smooth muscle from patients with myelomeningocele

AU - Hipp, Jennifer A.

AU - Hipp, Jason D.

AU - Yoo, James J.

AU - Atala, Anthony

AU - Andersson, Karl Erik

PY - 2008/9/1

Y1 - 2008/9/1

N2 - OBJECTIVE: To examine whether gene profiles can provide a molecular evaluation of the quality and therapeutic potential in patients with myelomeningocele (MM), by comparing genetic profiles of smooth muscle cells (SMCs) from healthy bladders and bladders from patients, to identify genes that are over- and under-expressed in MM bladder SMCs. MATERIAL AND METHODS: Bladder SM biopsies were obtained from 'healthy' subjects undergoing bladder surgery for vesico-ureteric reflux and from patients with a neurogenic bladder secondary to MM. Bladder SMCs were expanded in vitro and total RNA was isolated and hybridized to gene chips to evaluate the differential expression levels of 22 283 genes. Differentially expressed genes were identified by two methods. In the first analysis, we directly compared raw data sets of healthy SMCs to those derived from patients with MM. In the second analysis, we indirectly compared healthy SMCs and MM SMCs to a reference file, to create a genetic signature of genes that are over- and under-expressed in MM SMCs. RESULTS: The direct analysis identified 240 genes that were over-expressed and 104 that were under-expressed in MM SMCs. Gene ontology classifications were used to identify biological themes and pathways. Genes that were over-expressed in MM SMCs were involved in development: mesenchyme homeobox 2 (-fold change, 9.3); bone morphogenic protein 6 (4.0); fibroblast growth factor 2 (4.8); inhibin A (4.2), cartilage oliogomeric matrix protein (9.97); collagen 11A (6); collagen 5A2 (3) and collagen 1A1 (2.18). The indirect analysis identified 665 genes that were over-expressed and 1343 that were under-expressed in MM SMCs. Pathway-based analysis of these genetic signatures showed an over-expression of genes involved in muscle development and focal adhesion/extracellular matrix interactions. Genes that were under-expressed in MM SMCs were mapped to muscle contraction, transmission of nerve impulses, and cell-cell adhesion pathways. CONCLUSION: Our results are consistent with previous studies showing that MM bladders have an excess of extracellular matrix deposition, improper contraction, and are developmentally immature relatively to healthy SMCs. The clinical implication of microarray analysis of MM SMCs is that it provides potential targets that could induce muscle differentiation and inhibit extracellular matrix production.

AB - OBJECTIVE: To examine whether gene profiles can provide a molecular evaluation of the quality and therapeutic potential in patients with myelomeningocele (MM), by comparing genetic profiles of smooth muscle cells (SMCs) from healthy bladders and bladders from patients, to identify genes that are over- and under-expressed in MM bladder SMCs. MATERIAL AND METHODS: Bladder SM biopsies were obtained from 'healthy' subjects undergoing bladder surgery for vesico-ureteric reflux and from patients with a neurogenic bladder secondary to MM. Bladder SMCs were expanded in vitro and total RNA was isolated and hybridized to gene chips to evaluate the differential expression levels of 22 283 genes. Differentially expressed genes were identified by two methods. In the first analysis, we directly compared raw data sets of healthy SMCs to those derived from patients with MM. In the second analysis, we indirectly compared healthy SMCs and MM SMCs to a reference file, to create a genetic signature of genes that are over- and under-expressed in MM SMCs. RESULTS: The direct analysis identified 240 genes that were over-expressed and 104 that were under-expressed in MM SMCs. Gene ontology classifications were used to identify biological themes and pathways. Genes that were over-expressed in MM SMCs were involved in development: mesenchyme homeobox 2 (-fold change, 9.3); bone morphogenic protein 6 (4.0); fibroblast growth factor 2 (4.8); inhibin A (4.2), cartilage oliogomeric matrix protein (9.97); collagen 11A (6); collagen 5A2 (3) and collagen 1A1 (2.18). The indirect analysis identified 665 genes that were over-expressed and 1343 that were under-expressed in MM SMCs. Pathway-based analysis of these genetic signatures showed an over-expression of genes involved in muscle development and focal adhesion/extracellular matrix interactions. Genes that were under-expressed in MM SMCs were mapped to muscle contraction, transmission of nerve impulses, and cell-cell adhesion pathways. CONCLUSION: Our results are consistent with previous studies showing that MM bladders have an excess of extracellular matrix deposition, improper contraction, and are developmentally immature relatively to healthy SMCs. The clinical implication of microarray analysis of MM SMCs is that it provides potential targets that could induce muscle differentiation and inhibit extracellular matrix production.

KW - Bladder smooth muscle

KW - Microarray

KW - Myelomeningocele

UR - http://www.scopus.com/inward/record.url?scp=50049088447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50049088447&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2008.07606.x

DO - 10.1111/j.1464-410X.2008.07606.x

M3 - Article

C2 - 18336610

AN - SCOPUS:50049088447

VL - 102

SP - 741

EP - 746

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 6

ER -